Abbott Laboratories ABT NYSE

Abbott Laboratories (ABT) has shown moderate revenue growth over the past 3 years, expanding from $43.7B to $44.3B (average +0.7%/yr). Net income reached $6.5B, reflecting exceptional earnings expansion at +21.8%/yr on average. The net profit margin is 14.7%, which is moderate. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 55.5% (high), with a -0.6pp trend over the period. With a $176B market cap and MOAT composite score of 86/100, the company has a strong competitive position.

Criteria proven by this page:

• GROWTH (73/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 41-year history, the company was profitable in 41 of 41 years — a perfect long-term track record
• INCOME (55/100, Partial) — the company is profitable but margin is below 15%
• MOAT (86/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 80/100 with 5/7 criteria passed.